NextCell Pharma AB
STO:NXTCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.9), the stock would be worth kr0.87 (27% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.6 | kr1.19 |
0%
|
| 3-Year Average | 1.9 | kr0.87 |
-27%
|
| 5-Year Average | 2 | kr0.9 |
-24%
|
| Industry Average | 4.5 | kr2.03 |
+71%
|
| Country Average | 2.2 | kr0.99 |
-17%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
N
|
NextCell Pharma AB
STO:NXTCL
|
132.3m SEK | 2.6 | -2.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | -106.9 | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 21.1 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 7.1 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 5.9 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 2.5 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 6.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 2.3 | 30.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.2 |
| 70th Percentile | 3.7 |
| Max | 283.3 |
Other Multiples
NextCell Pharma AB
Glance View
NextCell Pharma AB engages in the development of stem cell products. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2017-07-13. The firm is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.
